Chemomab Therapeutics Spon Ads Each Rep 80 Ord Shs(p/s) (CMMB) Stock
Publicly traded company. Here's the price, business snapshot, and what's worth knowing about Chemomab Therapeutics Spon Ads Each Rep 80 Ord Shs(p/s) in October 2026.
Chemomab Therapeutics Ltd (formerly known as Anchiano Therapeutics Ltd) is a Israel-based clinical-stage biopharmaceutical company. The Company specializes in the development of patient oriented targeted therapy for the treatment of a wide range of fibrotic and inflammatory diseases with high unmet medical need among others. Its therapeutic and diagnostic technology, BC-819, constitutes a search paradigm for the targeted destruction of cancer cells with no effect on surrounding tissue and no observed side effects for long-term, safe treatment and prevention of cancer. The patient oriented targeted therapy approach is based on the identification of particular genes that are expressed only in tumors.
Chemomab Therapeutics Spon Ads Each Rep 80 Ord Shs(p/s) (CMMB) Stock Forecast
Analyst price target, next 12 months
$10.40
+637.6% vs today's $1.41
Price range over the last 12 months
Close to its 12-month low
Analysts covering Chemomab Therapeutics Spon Ads Each Rep 80 Ord Shs(p/s) have a consensus 12-month target of $10.40, above the current price of $1.41.
Analyst targets are opinions, not guarantees. Capital at risk. Data as of 28 Aug 2026.
Source: Analyst sentiment is provided by Refinitiv Ltd, a global leader in financial market data with over 40k business clients. Refinitiv Ltd is an independent third party to Nemo. This is not advice.
Sixth Month Growth Performance
Stock Performance Snapshot
Analyst Rating
Analysts believe Chemomab's stock is a great investment opportunity with potential for significant growth.
Financial Health
Chemomab Therapeutics shows a decent financial position with stable cash flow and book value.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
